98%
921
2 minutes
20
Autoimmune diseases (AIDs) are multifaceted, chronic illnesses characterized by immune dysregulation and systemic inflammation. Newer evidence has pointed a finger at the human gut microbiota, a trillion-fold population of microorganisms that inhabits the human GI tract, as a major influential modulator of immune reactivity and a significant contributor to autoimmune pathogenesis. This systematic review will seek to address how the literature correlates with systematic changes in the gut microbiota in AIDs as well as explore mechanistic associations with biological processes like intestinal permeability and modulation of the immune system, coupled with determining the effectiveness of microbiota-directed interventions. An extensive literature search was conducted in PubMed, Embase, Cochrane Central, and Web of Science, involving the availability of studies until May 2025. The eligible studies included observational studies, randomized controlled trials, and relevant mechanistic research regarding autoimmune diseases and alterations of the gut microbiome or administered interventions. Data extraction and risk of bias (ROB) assessments were performed by two independent reviewers, and a narrative synthesis with an illustrative meta-analysis was applied. Inclusion criteria were met by 10 studies, encompassing various autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), autoimmune thyroid diseases (AITDs), and psoriasis. Familiar patterns of microbiome dysbiosis were identified, such as a reduction in microbial diversity, increased intestinal permeability, and the expansion of pro-inflammatory species like . Dietary interventions, fecal microbiota transplantation, and probiotics demonstrated positive effects on clinical outcomes and immune measures across multiple studies. The meta-analysis revealed that microbiota-directed interventions significantly improved disease activity and immune response markers in AIDs, indicating a robust link between gut microbiota composition and autoimmune pathology. In autoimmune disorders, gut microbiota is a key factor in immunopathology. Gut biology as an adjunct interventional strategy provides potential in managing these diseases. Additional studies are required to help standardize methods and identify microbial targets specific to diseases that can then be addressed through therapeutic interventions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404852 | PMC |
http://dx.doi.org/10.7759/cureus.89300 | DOI Listing |
United European Gastroenterol J
September 2025
Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy.
Background: Few data are available on the impact of primary sclerosing cholangitis (PSC) on inflammatory bowel disease (IBD).
Objective: We conducted a retrospective study using TriNetX to compare the outcomes of patients with IBD and those with concomitant IBD and PSC.
Methods: All patients with a confirmed diagnosis of Crohn's disease (CD), ulcerative colitis (UC), or indeterminate colitis with or without PSC were eligible.
Cell Mol Biol (Noisy-le-grand)
September 2025
M-DT1, Roquefort-les Pins, France.
To date, the closed-loop system represents the best commercialized management of type 1 diabetes. However, mealtimes still require carbohydrate estimation and are often associated with postprandial hyperglycemia which may contribute to poor metabolic control and long -term complications. A multicentre, prospective, non-interventional clinical trial was designed to determine the effectiveness of a novel algorithm to predict changes in blood glucose levels two hours after a usual meal.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Department of Chemistry, Faculty of Science and Health, Koya University, Koya, KOY45, Kurdistan Region, Iraq.
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation. Given the side effects of conventional treatments, this study focuses on the anti-inflammatory effects of purslane (Portulaca oleracea) and turmeric (Curcuma longa). The research is driven by the growing demand for plant based-treatment for safer therapeutic options for RA management.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Department of Dentistry, Al-Esraa University, Baghdad, Iraq.
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation and is often associated with poor oral health. Cytokines play a central role in RA immunopathogenesis. This case-control study investigated the involvement of salivary interleukin-17A (IL-17A) and interleukin-18 (IL-18) in RA patients in relation to oral health status.
View Article and Find Full Text PDFBioDrugs
September 2025
Department of Nephrology, Instituto de Investigación Hospital "12 de Octubre" (imas12), Avda. De Córdoba s/n, 28041, Madrid, Spain.
Anti-CD20 monoclonal antibodies are gaining clinical relevance in the nephrology community due to their demonstrated efficacy and favorable safety profiles across short-, medium-, and long-term use. Initially developed for hematologic malignancies and multiple sclerosis, B-cell depletion therapies are now being investigated across a broader spectrum of autoimmune diseases, including glomerulopathies, both with and without associated podocytopathy. Recent advances have led to the development of novel anti-CD20 agents that are being used not only as potential alternatives to corticosteroids but also as adjunctive therapies in complex clinical settings.
View Article and Find Full Text PDF